UPDATE: Goldman Sachs Starts Pacira Pharmaceuticals (PCRX) at Neutral
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
(Updated - December 1, 2016 10:10 AM EST)
Goldman Sachs initiated coverage on Pacira Pharmaceuticals (NASDAQ: PCRX) with a Neutral rating and a price target of $36. Analyst Stephan Stewart sees balanced risk/reward heading into study data.
"While growth for its only drug, Exparel, continues to decelerate post warning letter resolution, our physician/surgeon survey highlights continued penetration opportunity for the drug. That said, any eventual inflection will be dependent on PCRX’s success across a host of drivers, most notably its ongoing Phase 3 study for a nerve block indication. While we are optimistic that this study will yield positive data – based on previous data – consensus estimates already largely reflect the associated inflection, creating relatively balanced risk/reward at these levels in our view," said the analyst.
Shares of Pacira Pharmaceuticals closed at $31.85 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- M&T Bank (MTB) PT Raised to $165 at FBR Capital Following 4Q Beat
- Carter's (CRI) PT Lowered to $105 at Oppenheimer; Reiterates Outperform
- Drexel Hamilton Reiterates Buy on IBM (IBM) Following 4Q Report
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View, New Coverage
Related EntitiesGoldman Sachs
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!